Congenital (TORCH) infections — neonatal approach
SGA, rash, calcifications · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Congenital infections (toxoplasmosis, other [syphilis, VZV, parvovirus], rubella, CMV, HSV) are acquired in utero and share overlapping features — growth restriction, hepatosplenomegaly, jaundice, rash, thrombocytopenia, and CNS/eye/hearing involvement. CMV is the commonest; the approach is to recognise the pattern, identify the organism, and treat where effective therapy exists.
Red flags
- Microcephaly, seizures or abnormal neuro-imaging
- Thrombocytopenia with petechiae/purpura ('blueberry muffin' rash)
- Conjugated hyperbilirubinaemia and hepatosplenomegaly
- Vesicular rash or sepsis (consider HSV — treat empirically)
- Failed newborn hearing screen
Assessment
Differential diagnosis
- Congenital CMV
- Congenital toxoplasmosis
- Congenital rubella syndrome
- Congenital syphilis
- Neonatal HSV / congenital varicella
- Early-onset bacterial sepsis (mimic)
Investigations
- Congenital CMV: urine/saliva CMV PCR within the first 21 days of life (diagnostic window)
- Toxoplasma, rubella, syphilis (VDRL/TPPA) serology on infant and mother
- FBC, LFTs, conjugated bilirubin, coagulation
- Cranial ultrasound/MRI (calcifications, ventriculomegaly, migration anomalies)
- Ophthalmology review (chorioretinitis, cataract) and formal hearing screen (AABR)
- Lumbar puncture/CSF and long-bone X-rays where syphilis or specific organism suspected
Management
- Suspect congenital infection in any growth-restricted or symptomatic neonate with multisystem signs
- Send targeted virology/serology, prioritising CMV PCR before 21 days of age
- Image the brain and arrange ophthalmology and audiology assessment
- Check platelets, liver function and coagulation
- Confirm the specific organism before committing to prolonged therapy
- Treat symptomatic congenital CMV with oral valganciclovir (or IV ganciclovir) for 6 months with blood monitoring
- Treat congenital toxoplasmosis with pyrimethamine + sulfadiazine + folinic acid for ~12 months
- Treat congenital syphilis with IV/IM penicillin per staging
- Arrange long-term audiology and neurodevelopmental follow-up (progressive hearing loss in CMV)
- Involve maternal/infectious diseases services and discuss prevention in future pregnancies
Drugs & doses
Valganciclovir 16 mg/kg/dose PO twice daily for 6 months (symptomatic congenital CMV); IV ganciclovir 6 mg/kg/dose 12-hourly if enteral not tolerated
Pyrimethamine + sulfadiazine + folinic acid (calcium folinate) for congenital toxoplasmosis (~12 months)
Benzylpenicillin 50 mg/kg/dose IV (frequency by age) for 10 days for congenital syphilis
Aciclovir 20 mg/kg/dose IV 8-hourly if neonatal HSV suspected
Disposition
Neonatal unit/outpatient work-up with infectious diseases input; start organism-specific therapy. Enrol in long-term audiology, ophthalmology and neurodevelopmental follow-up.
Complications & pitfalls
- Sensorineural hearing loss (often progressive, especially CMV)
- Neurodevelopmental impairment and epilepsy
- Visual impairment from chorioretinitis/cataract
- Hydrops/anaemia (parvovirus)
- Bleeding from thrombocytopenia
Exam pearls
- CMV PCR must be collected within the first 3 weeks of life to prove congenital (vs postnatal) infection
- Antiviral treatment of symptomatic CMV improves hearing and neurodevelopmental outcomes
- A vesicular rash or sepsis-like picture should trigger empirical HSV therapy while testing
- All suspected congenital infections need audiology and ophthalmology surveillance
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.